Eagle Pharmaceutical (EGRX) 44.56 $EGRX
INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Eagle Pharmaceuticals, Inc. and a Lead Plaintiff Deadline of August 1, 2016 - EGRX
PR Newswire - Fri Jul 08, 10:06AM CDT
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of New Jersey on behalf of investors who purchased Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) securities between February 23, 2016 through March 18, 2016.
EGRX: 44.56 (+1.78)
DEADLINE ALERT - EAGLE PHARMACEUTICALS, INC. - Brower Piven Reminds Shareholders of Approaching Deadline In Class Action Lawsuit And Encourages Investors Who Have Losses In Excess of $100,000 To Contact The Firm
BusinessWire - Tue Jul 05, 1:40PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of purchasers of Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle" or the "Company"
securities during the period between February 23, 2016 through March 18, 2016, inclusive (the "Class Period" . Investors with losses in excess of $100,000 who wish to become proactively involved in the litigation have until August 1, 2016 to seek appointment as lead plaintiff.
EGRX: 44.56 (+1.78)
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Eagle Pharmaceuticals, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 1, 2016
BusinessWire - Tue Jul 05, 9:36AM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
EGRX: 44.56 (+1.78)
Eagle Pharmaceuticals Announces Changes to Its Board of Directors; Director, Michael Graves Appointed Chairman
BusinessWire - Tue Jul 05, 6:00AM CDT
--Hudson Executive Capital LP acquires 6.1% equity interest in Eagle
JPM: 62.27 (+0.44), EGRX: 44.56 (+1.78)
IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces the Filing of a Securities Class Action Lawsuit Against Eagle Pharmaceuticals Inc. and Reminds Investors With Losses to Contact the Firm
BusinessWire - Fri Jul 01, 7:47PM CDT
Khang & Khang LLP (the "Firm" announces that a class action lawsuit has been filed against Eagle Pharmaceuticals Inc. ("Eagle" or the "Company" (Nasdaq: EGRX). Investors who purchased or otherwise acquired shares between February 23, 2016 and March 18, 2016 inclusive (the "Class Period" , are encouraged to contact the Firm prior to the August 1, 2016 lead plaintiff motion deadline.
EGRX: 44.56 (+1.78)
Eagle Pharmaceuticals Founder, President & CEO Scott Tarriff Named EY Entrepreneur Of The Year(R) 2016 New Jersey Region
BusinessWire - Mon Jun 27, 6:30AM CDT
Eagle Pharmaceuticals (NASDAQ:EGRX) is pleased to announce that Founder, President and CEO Scott Tarriff received the EY Entrepreneur Of The Year(R) 2016 Award in the Specialty Pharmaceutical category in New Jersey. This year marks the 30th anniversary of the EY Entrepreneur Of The Year Award program. The award recognizes outstanding entrepreneurs who demonstrate excellence and extraordinary success in such areas as innovation, financial performance, and personal commitment to their businesses and communities. Mr. Tarriff was selected by an independent panel of judges, and the award was presented at a special gala event at the Hyatt Regency, New Brunswick on June 23, 2016.
EGRX: 44.56 (+1.78)
IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit against Eagle Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
BusinessWire - Wed Jun 22, 4:51PM CDT
Goldberg Law PC (www.Goldberglawpc.com) announces that a class action lawsuit has been filed against Eagle Pharmaceuticals, Inc. ("Eagle Pharmaceuticals" or the "Company" (Nasdaq: EGRX). Investors who purchased or otherwise acquired shares between February 23, 2016 and March 18, 2016 (the "Class Period" , are encouraged to contact the firm in advance of the August 1, 2016, lead plaintiff motion deadline.
EGRX: 44.56 (+1.78)
INVESTOR ALERT: Investigation of Eagle Pharmaceuticals Inc. Announced by Law Offices of Howard G. Smith
BusinessWire - Wed Jun 22, 1:39PM CDT
Law Offices of Howard G. Smith announces an investigation on behalf of investors of Eagle Pharmaceuticals Inc. ("Eagle" or the "Company" (NASDAQ: EGRX) concerning the Company and its officers' possible violations of federal securities laws.
EGRX: 44.56 (+1.78)
EAGLE PHARMACEUTICALS INVESTOR ALERT: Hagens Berman Reminds Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) Investors of August 1, 2016 Lead Plaintiff Deadline in Securities Class Action
GlobeNewswire - Tue Jun 21, 3:00AM CDT
The following statement is being issued by Hagens Berman Sobol Shapiro LLP:
EGRX: 44.56 (+1.78)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Eagle Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 1, 2016 - EGRX
GlobeNewswire - Mon Jun 20, 10:51AM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
EGRX: 44.56 (+1.78)
Lifshitz & Miller Law Firm Announces Investigation of CBL & Associates Properties, Inc., Eagle Pharmaceuticals, Inc., HCP, Inc., Immunomedics, Inc., Infinity Pharmaceuticals Inc., Neovasc, Inc., and Unilife Corporation
PR Newswire - Fri Jun 17, 6:09PM CDT
CBL & Associates Properties, Inc. (CBL)Lifshitz & Miller announces investigation into possible breaches of fiduciary duties by the CBL board. Specifically, on May 24, 2016, the Wall Street Journal reported investigations concerning CBL officials falsifying information on financial statements to banks when applying for financial arrangements.
IMMU: 2.30 (-0.18), HCP: 36.54 (+0.60), UNIS: 3.46 (-0.02), CBL: 10.59 (+0.51), INFI: 1.42 (+0.02), EGRX: 44.56 (+1.78), NVCN: 0.47 (-0.02)
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Eagle Pharmaceuticals, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 1, 2016 - EGRX
ACCESSWIRE - Wed Jun 15, 9:04AM CDT
NEW YORK, NY / ACCESSWIRE / June 15, 2016 / The following statement is being issued by Levi & Korsinsky, LLP:
EGRX: 44.56 (+1.78)
Law Offices of Marc S. Henzel Announces Investigation of Companies for Violations of the Federal Securities Laws
PR Newswire - Tue Jun 14, 8:11AM CDT
The Law Offices of Marc S. Henzel (www.henzellaw.com), a firm focusing on shareholder litigation, gives notice to shareholders of investigation into the following securities for violations of the Federal Securities Laws:
LDRH: 37.00 (+0.03), CBL: 10.59 (+0.51), TRXC: 1.31 (+0.04), EGRX: 44.56 (+1.78), NVCN: 0.47 (-0.02)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Eagle Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - EGRX
PR Newswire - Fri Jun 10, 4:42PM CDT
Pomerantz LLP announces that a class action lawsuit has been against Eagle Pharmaceuticals, Inc. ("Eagle Pharmaceuticals" or the "Company" (NASDAQ: EGRX) and certain of its officers. The class action, filed in United States District Court, District of New Jersey, and docketed under 16-cv-03091, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Eagle Pharmaceuticals securities between February 23, 2016 and March 18, 2016 inclusive (the "Class Period" . This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act" .
EGRX: 44.56 (+1.78)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Eagle Pharmaceuticals, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 1, 2016 -- EGRX
Marketwired - Fri Jun 10, 11:37AM CDT
NEW YORK, NY--(Marketwired - June 10, 2016) - The following statement is being issued by Levi & Korsinsky, LLP:
EGRX: 44.56 (+1.78)
IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Claims Against Eagle Pharmaceuticals Inc. and Advises Investors With Losses to Contact the Firm
BusinessWire - Wed Jun 08, 2:39PM CDT
Goldberg Law PC (http://www.Goldberglawpc.com) announces that it is investigating claims of potential misrepresentations by Eagle Pharmaceuticals Inc. ("Eagle" or the "Company" (Nasdaq: EGRX). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors.
EGRX: 44.56 (+1.78)
EAGLE PHARMACEUTICALS INVESTOR ALERT: Hagens Berman Alerts Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) Investors to Securities Class Action and August 1, 2016 Lead Plaintiff Deadline
GlobeNewswire - Tue Jun 07, 7:30AM CDT
The following statement is being issued by Hagens Berman Sobol Shapiro LLP:
EGRX: 44.56 (+1.78)
INVESTOR NOTICE: Khang & Khang LLP Announces an Investigation of Claims against Eagle Pharmaceuticals Inc. and Advises Investors to Contact the Firm
BusinessWire - Mon Jun 06, 8:34PM CDT
Khang & Khang LLP announces that it is investigating claims of potential misrepresentations by Eagle Pharmaceuticals Inc. ("Eagle Pharmaceuticals" or the "Company" (Nasdaq: EGRX). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors.
EGRX: 44.56 (+1.78)
Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Eagle Pharmaceuticals Inc.
PR Newswire - Mon Jun 06, 6:15PM CDT
Ryan & Maniskas, LLP announces that a class action lawsuit has been filed in United States District Court for the District of New Jersey on behalf of purchasers of Eagle Pharmaceuticals Inc. ("Eagle Pharmaceuticals" or the "Company" (NASDAQ: EGRX) common stock during the period between February 23, 2016 and March 18, 2016, inclusive (the "Class Period" .
EGRX: 44.56 (+1.78)
INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Eagle Pharmaceuticals, Inc. and a Lead Plaintiff Deadline of August 1, 2016 - EGRX
PR Newswire - Fri Jul 08, 10:06AM CDT
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of New Jersey on behalf of investors who purchased Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) securities between February 23, 2016 through March 18, 2016.
EGRX: 44.56 (+1.78)
DEADLINE ALERT - EAGLE PHARMACEUTICALS, INC. - Brower Piven Reminds Shareholders of Approaching Deadline In Class Action Lawsuit And Encourages Investors Who Have Losses In Excess of $100,000 To Contact The Firm
BusinessWire - Tue Jul 05, 1:40PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of purchasers of Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle" or the "Company"
securities during the period between February 23, 2016 through March 18, 2016, inclusive (the "Class Period" . Investors with losses in excess of $100,000 who wish to become proactively involved in the litigation have until August 1, 2016 to seek appointment as lead plaintiff. EGRX: 44.56 (+1.78)
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Eagle Pharmaceuticals, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 1, 2016
BusinessWire - Tue Jul 05, 9:36AM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
EGRX: 44.56 (+1.78)
Eagle Pharmaceuticals Announces Changes to Its Board of Directors; Director, Michael Graves Appointed Chairman
BusinessWire - Tue Jul 05, 6:00AM CDT
--Hudson Executive Capital LP acquires 6.1% equity interest in Eagle
JPM: 62.27 (+0.44), EGRX: 44.56 (+1.78)
IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces the Filing of a Securities Class Action Lawsuit Against Eagle Pharmaceuticals Inc. and Reminds Investors With Losses to Contact the Firm
BusinessWire - Fri Jul 01, 7:47PM CDT
Khang & Khang LLP (the "Firm"
announces that a class action lawsuit has been filed against Eagle Pharmaceuticals Inc. ("Eagle" or the "Company" (Nasdaq: EGRX). Investors who purchased or otherwise acquired shares between February 23, 2016 and March 18, 2016 inclusive (the "Class Period" , are encouraged to contact the Firm prior to the August 1, 2016 lead plaintiff motion deadline. EGRX: 44.56 (+1.78)
Eagle Pharmaceuticals Founder, President & CEO Scott Tarriff Named EY Entrepreneur Of The Year(R) 2016 New Jersey Region
BusinessWire - Mon Jun 27, 6:30AM CDT
Eagle Pharmaceuticals (NASDAQ:EGRX) is pleased to announce that Founder, President and CEO Scott Tarriff received the EY Entrepreneur Of The Year(R) 2016 Award in the Specialty Pharmaceutical category in New Jersey. This year marks the 30th anniversary of the EY Entrepreneur Of The Year Award program. The award recognizes outstanding entrepreneurs who demonstrate excellence and extraordinary success in such areas as innovation, financial performance, and personal commitment to their businesses and communities. Mr. Tarriff was selected by an independent panel of judges, and the award was presented at a special gala event at the Hyatt Regency, New Brunswick on June 23, 2016.
EGRX: 44.56 (+1.78)
IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit against Eagle Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
BusinessWire - Wed Jun 22, 4:51PM CDT
Goldberg Law PC (www.Goldberglawpc.com) announces that a class action lawsuit has been filed against Eagle Pharmaceuticals, Inc. ("Eagle Pharmaceuticals" or the "Company"
(Nasdaq: EGRX). Investors who purchased or otherwise acquired shares between February 23, 2016 and March 18, 2016 (the "Class Period" , are encouraged to contact the firm in advance of the August 1, 2016, lead plaintiff motion deadline. EGRX: 44.56 (+1.78)
INVESTOR ALERT: Investigation of Eagle Pharmaceuticals Inc. Announced by Law Offices of Howard G. Smith
BusinessWire - Wed Jun 22, 1:39PM CDT
Law Offices of Howard G. Smith announces an investigation on behalf of investors of Eagle Pharmaceuticals Inc. ("Eagle" or the "Company"
(NASDAQ: EGRX) concerning the Company and its officers' possible violations of federal securities laws. EGRX: 44.56 (+1.78)
EAGLE PHARMACEUTICALS INVESTOR ALERT: Hagens Berman Reminds Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) Investors of August 1, 2016 Lead Plaintiff Deadline in Securities Class Action
GlobeNewswire - Tue Jun 21, 3:00AM CDT
The following statement is being issued by Hagens Berman Sobol Shapiro LLP:
EGRX: 44.56 (+1.78)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Eagle Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 1, 2016 - EGRX
GlobeNewswire - Mon Jun 20, 10:51AM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
EGRX: 44.56 (+1.78)
Lifshitz & Miller Law Firm Announces Investigation of CBL & Associates Properties, Inc., Eagle Pharmaceuticals, Inc., HCP, Inc., Immunomedics, Inc., Infinity Pharmaceuticals Inc., Neovasc, Inc., and Unilife Corporation
PR Newswire - Fri Jun 17, 6:09PM CDT
CBL & Associates Properties, Inc. (CBL)Lifshitz & Miller announces investigation into possible breaches of fiduciary duties by the CBL board. Specifically, on May 24, 2016, the Wall Street Journal reported investigations concerning CBL officials falsifying information on financial statements to banks when applying for financial arrangements.
IMMU: 2.30 (-0.18), HCP: 36.54 (+0.60), UNIS: 3.46 (-0.02), CBL: 10.59 (+0.51), INFI: 1.42 (+0.02), EGRX: 44.56 (+1.78), NVCN: 0.47 (-0.02)
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Eagle Pharmaceuticals, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 1, 2016 - EGRX
ACCESSWIRE - Wed Jun 15, 9:04AM CDT
NEW YORK, NY / ACCESSWIRE / June 15, 2016 / The following statement is being issued by Levi & Korsinsky, LLP:
EGRX: 44.56 (+1.78)
Law Offices of Marc S. Henzel Announces Investigation of Companies for Violations of the Federal Securities Laws
PR Newswire - Tue Jun 14, 8:11AM CDT
The Law Offices of Marc S. Henzel (www.henzellaw.com), a firm focusing on shareholder litigation, gives notice to shareholders of investigation into the following securities for violations of the Federal Securities Laws:
LDRH: 37.00 (+0.03), CBL: 10.59 (+0.51), TRXC: 1.31 (+0.04), EGRX: 44.56 (+1.78), NVCN: 0.47 (-0.02)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Eagle Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - EGRX
PR Newswire - Fri Jun 10, 4:42PM CDT
Pomerantz LLP announces that a class action lawsuit has been against Eagle Pharmaceuticals, Inc. ("Eagle Pharmaceuticals" or the "Company"
(NASDAQ: EGRX) and certain of its officers. The class action, filed in United States District Court, District of New Jersey, and docketed under 16-cv-03091, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Eagle Pharmaceuticals securities between February 23, 2016 and March 18, 2016 inclusive (the "Class Period" . This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act" . EGRX: 44.56 (+1.78)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Eagle Pharmaceuticals, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 1, 2016 -- EGRX
Marketwired - Fri Jun 10, 11:37AM CDT
NEW YORK, NY--(Marketwired - June 10, 2016) - The following statement is being issued by Levi & Korsinsky, LLP:
EGRX: 44.56 (+1.78)
IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Claims Against Eagle Pharmaceuticals Inc. and Advises Investors With Losses to Contact the Firm
BusinessWire - Wed Jun 08, 2:39PM CDT
Goldberg Law PC (http://www.Goldberglawpc.com) announces that it is investigating claims of potential misrepresentations by Eagle Pharmaceuticals Inc. ("Eagle" or the "Company"
(Nasdaq: EGRX). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors. EGRX: 44.56 (+1.78)
EAGLE PHARMACEUTICALS INVESTOR ALERT: Hagens Berman Alerts Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) Investors to Securities Class Action and August 1, 2016 Lead Plaintiff Deadline
GlobeNewswire - Tue Jun 07, 7:30AM CDT
The following statement is being issued by Hagens Berman Sobol Shapiro LLP:
EGRX: 44.56 (+1.78)
INVESTOR NOTICE: Khang & Khang LLP Announces an Investigation of Claims against Eagle Pharmaceuticals Inc. and Advises Investors to Contact the Firm
BusinessWire - Mon Jun 06, 8:34PM CDT
Khang & Khang LLP announces that it is investigating claims of potential misrepresentations by Eagle Pharmaceuticals Inc. ("Eagle Pharmaceuticals" or the "Company"
(Nasdaq: EGRX). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors. EGRX: 44.56 (+1.78)
Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Eagle Pharmaceuticals Inc.
PR Newswire - Mon Jun 06, 6:15PM CDT
Ryan & Maniskas, LLP announces that a class action lawsuit has been filed in United States District Court for the District of New Jersey on behalf of purchasers of Eagle Pharmaceuticals Inc. ("Eagle Pharmaceuticals" or the "Company"
(NASDAQ: EGRX) common stock during the period between February 23, 2016 and March 18, 2016, inclusive (the "Class Period" . EGRX: 44.56 (+1.78)
